HIV / AIDS

Jake Glaser explains the challenges faced when fundraising for AIDS programs in the 21st century.

Questions regarding a finance executive’s expertise in infectious diseases aside, the move seems straightforward enough—at least on the surface.

A new study examines HCV treatment uptake in HCV patients coinfected with HIV.

A new announcement marks the elimination of mother-to-child HIV transmission in 6 Caribbean territories and states

The National Institutes of Health (NIH) have announced plans for a new trial testing the effectiveness of the injectable pre-exposure prophylaxis (PrEP) drug, cabotegravir, in sexually-active women.

Jake Glaser shares who he feels is going to end the AIDS epidemic.

Although much has changed since the first World AIDS Day in 1988, the effects of the disease on public health remain significant, even as more individuals are “living” with the virus and fewer are dying from it.

Jake Glaser shares what is needed to achieve the Fast-Track strategy to end the AIDS epidemic by 2030.

Individuals with cancer and HIV used to be excluded from clinical trials due to safety concerns, but new positive results open up treatment avenues for this population.

The FDA has approved Merck’s ISENTRESS to be used in combination with other antiretroviral agents to treat HIV-1 in certain newborns.

Many individuals live with HIV for years before they are aware of their status. HIV testing is crucial if we hope to bring a close to the ongoing epidemic.

Researchers in South Africa have developed a symptom score card to help diagnose tuberculosis infections in individuals with HIV.

In case you missed them, we've compiled the top five infectious disease articles from this past week.

The FDA has just approved the first two-drug regimen for treating certain individuals living with HIV.

We cover 10 things you need to know about HIV viral suppression, according to the National Institute of Allergy and Infectious Diseases.

Treatment with a protease inhibitor plus raltegravir was found to offer no benefit over a protease inhibitor plus nucleoside reverse-transcriptase inhibitor regimen in patients with HIV.

The American Academy of HIV Medicine (AAHIVM) has partnered with the All of Us Research Program, part of the National Institutes of Health, to join in efforts to raise awareness about the program.

Clinicians should counsel individuals with HIV on avoiding health-related behaviors that may alter their gut microbiota and instead practices those that may decrease inflammation.

Studies have proven that undetectable levels of HIV mean an individual cannot transmit the virus to someone else. Now the word needs to spread.

Although a once-daily pill to prevent HIV exists, US populations at highest risk have the lowest rates of usage.

In a story that could be straight out of the 1980s, health officials in the state of West Virginia have stated they are dealing with a major outbreak of HIV infections in the southern part of the state.

Remembering the links between infectious diseases such as influenza and HIV, among others, and mental health can improve patient outcomes.

Recent data demonstrated that small doses of raltegravir could lead patients developing malignancies; however, the observations had not yet been substantiated.

Obesity is found to be a driver of this process.

Dolutegravir seemed to be a promising maintenance monotherapy for people living with HIV, but the development of resistance mutations in testing strikes it from the list.